Embla Medical hf
Research Embla Medical hf (EMBLA) on Bullrun: valuation model: 44.9% undervalued, market cap DKK 11.25B, P/E 20.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEMBLA
- ExchangeCO
- CountryIceland
- SectorHealthcare
- IndustryMedical Devices
- CurrencyDKK
- Valuation signal44.9% undervalued
- Market capDKK 11.25B
- P/E20.2
- Financial periodQ1 2026
- RevenueDKK 232.40M
- Net incomeDKK 14.46M
- Free cash flowDKK 3.87M
- Gross margin61.6%
Valuation Snapshot
Bullrun's latest valuation model marks Embla Medical hf as 44.9% undervalued; latest market cap is DKK 11.25B; P/E is 20.2.
About Embla Medical hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints.
Frequently asked questions
Is Embla Medical hf overvalued or undervalued?
Bullrun's valuation model currently marks Embla Medical hf as 44.9% undervalued.
What is Embla Medical hf's market cap?
Embla Medical hf's market capitalization is DKK 11.25B.
What is Embla Medical hf's P/E ratio?
Embla Medical hf's price-to-earnings (P/E) ratio is 20.2.
What does Embla Medical hf do?
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care.